Highly expressed STING in liver metastasis of uveal melanoma can lead to synergistic killing

Eye cancer that spreads to the liver is one of the most difficult challenges in modern medicine. When a specific type of eye cancer called uveal melanoma moves from the eye to the liver, it becomes extremely aggressive and hard to treat. Current treatments often provide only a short delay in the disease's progression, and the body's natural immune defenses frequently fail to stop the cancer cells from growing. Scientists have long known that a specific genetic change, the loss of a protein called BAP1, is a major warning sign that this cancer will spread. However, the exact way this genetic loss helps the cancer survive and grow has remained a mystery, leaving doctors without a clear target for new drugs.

Researchers at Thomas Jefferson University and Wills Eye Hospital have now uncovered a surprising feature of these spreading cancer cells that could change how they are treated. They discovered that when uveal melanoma cells travel to the liver, they carry a massive amount of a specific protein called STING. In healthy liver cells, this protein is essentially absent, but in the cancer cells, it is present in very high numbers. This protein acts as a sensor inside the cell, designed to detect danger like viral infections or DNA damage. While the researchers found that the cancer cells are full of this sensor, they also found that the cells are not using it to fight themselves. Instead, the cancer cells seem to keep the sensor in a dormant state, waiting. The team found that by waking up this sensor with a specific drug, and then blocking the cell's ability to clean up the resulting mess with a second drug, they could trigger a rapid and powerful self-destruction in the cancer cells.

The investigation began with a simple observation of tissue samples taken from patients whose uveal melanoma had spread to their livers. The researchers used a staining technique to look for the presence of the STING protein. They found that every single cancer cell in these liver samples was packed with the protein, glowing brightly under the microscope. In stark contrast, the healthy liver cells surrounding the tumors showed no sign of the protein at all. This pattern held true across sixteen different patient samples and was also confirmed in laboratory models where human tumors were grown in mice. The researchers then looked at the primary tumors in the eyes before they had spread. They found that while some of these early-stage tumors had high levels of the protein, many had very low levels. This suggested that the cancer cells might be accumulating this protein specifically as they become more aggressive and spread to the liver.

To understand why this protein was so abundant in the spreading cancer, the team looked at the genetic instructions inside the cells. They analyzed data from thousands of tumor samples and found a clear link: when the BAP1 gene was broken or missing, the cells produced much more of the STING protein. This confirmed that the genetic change known to drive the spread of the cancer was directly responsible for loading the cells with this sensor. The researchers then tested how these cells reacted when they were forced to use this sensor. They treated the cancer cells with a drug designed to activate STING. In cells that had the broken BAP1 gene, the sensor stayed active for a long time. In cells with normal BAP1, the sensor was quickly turned off and broken down. This difference suggested that the broken BAP1 gene not only loaded the cells with the sensor but also prevented the cell from turning it off.

The real breakthrough came when the researchers tried to combine this activation with another type of drug. They knew that when STING is activated, the cell tries to get rid of the active protein to stop the signal. They used a drug called bortezomib, which is already approved to treat a different type of blood cancer, to block the cell's cleanup system. When they treated the uveal melanoma cells with both the STING-activating drug and the cleanup blocker, the result was immediate and devastating for the cancer. The cells began to die within hours. The combination worked so well that the researchers calculated a very high score for how much the two drugs helped each other, a phenomenon known as synergy. This means the drugs were far more effective together than the sum of their individual effects.

Crucially, this deadly combination did not harm healthy cells. The researchers tested the drugs on normal human blood cells and found no signs of damage. They also tested them on cancer cells from the lung, kidney, and cervix, and those cells survived the treatment. This selectivity is vital, as it suggests the treatment could target the eye cancer without causing widespread sickness to the patient. The researchers confirmed that this effect was not just a fluke of the specific drugs they chose. When they swapped in different drugs that work in the same way, the cancer cells still died, proving that the mechanism itself was the key.

The study suggests that the high levels of STING in these liver metastases are a vulnerability that can be exploited. While the cancer cells have evolved to carry this protein, they have not evolved a way to survive when it is forced to stay active while their cleanup system is blocked. The researchers found that this lethal effect happened regardless of whether the cancer cells had the broken BAP1 gene or not, indicating that the high level of STING itself is the target. The findings point toward a potential new strategy for treating this difficult disease: waking up a dormant defense mechanism inside the cancer cell and preventing it from shutting down, causing the cell to destroy itself. While these results were observed in the laboratory, the researchers note that the drugs used are already known to be safe for humans, which could allow this approach to move quickly into clinical testing to see if it can save lives in patients with metastatic uveal melanoma.